BioCentury
ARTICLE | Company News

Lodo, Genentech partner on R&D for microbial-derived therapies

May 11, 2018 6:33 PM UTC

Lodo Therapeutics Corp. (New York, N.Y.) and the Genentech Inc. unit of Roche (SIX:ROG; OTCQB:RHHBY) partnered to discover compounds with Lodo's Metagenomics Technology Platform against multiple undisclosed targets chosen by Genentech. The collaboration could potentially cover multiple diseases, including infectious diseases and cancer, according to Genentech Director of Research Tools & Technologies Business Development Mark Rowen.

Under the deal, Lodo will receive an undisclosed upfront payment and is eligible for R&D and commercialization milestones up to $969 million, plus tiered royalties on sales. Genentech will have worldwide rights to therapies developed under the collaboration, according to Lodo co-founder and CSO David Pompliano...